• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Program

Preliminary program now available!

The APLAR 2023 official program is scheduled in the Chiang Mai time zone (GMT+7). To check the program times in your location, use our time zone converter

As more information becomes available – this page will be updated so please make sure to check back regularly. 

0800
REGISTRATION
0830-0900
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 1
Workshop begins at 0830.

View information here
0900-1200
MRI Axial Imaging Course
Course begins at 0900.

View information here
1200-1245
BREAK
1245-1445
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 1
Continued
MRI Axial Imaging Course
Continued
1445-1515
BREAK
1515-1700
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 1
Continued - Workshop finishes at 1700 for this day.
MRI Axial Imaging Course
Course finishes at 1600.
0800-0830
REGISTRATION
0830-0900
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 2
Continued - Workshop begins at 0830.

View information here
0900-1000
mRSS Assessment Course
Course will run between 0900 - 1015 before the break

View Information here
1000 -1030
BREAK
1030 -1200
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 2
Continued
mRSS Assessment Course
Course finishes at 1200, noon
1200 -1245
BREAK
1245 -1400
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 2
Continued
AYR Clinical Skills workshop -labial salivary gland biopsy and muscle biopsy

View information here
GRAPPA Symposium
Symposium begins at 1330.

View information here
mRSS Assessment Course - REPEATED COURSE
Course begins at 1330.

View Information here
1430 -1500
BREAK
1500 -1630
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 2
Continued - Workshop continues until 1700.
Changing and perspective of academic journals

View information here
GRAPPA Symposium
Symposium finishes at 1630.
mRSS Assessment Course - REPEATED COURSE
Course finishes at 1630
1700-1800
Opening Ceremony
Included in registration. View more information here
1800-1930
Welcome Reception and Official Opening of Exhibition Hall
Included in registration. View more information here
ROOM
Capacity
B7
150 theatre capacity
B2
50 classroom capacity
B8
150 classroom capacity
B9
250 theatre capacity
--
Info coming soon
B3
100 classroom capacity
B4
100 classroom capacity
B5
100 classroom capacity
A2
30 u-shape
0830-0900
REGISTRATION
0900-1000
Cont.
MSUS Workshop
Day 2
Cont.
MRI Imaging Course
Day 2
GRAPPA Symposium
Allied Health Course
APLAR Industry workshop 1

set up
APLAR Industry workshop 2

set up
APLAR Industry workshop 3

set up
APLAR Executive Committee Meeting
1000 -1030
COFFEE BREAK
COFFEE BREAK
1030 -1200
Cont.
MSUS Workshop
Day 2
Cont.
MRI Imaging Course
Day 2
Cont.
GRAPPA Symposium
Cont.
Allied Health Course
APLAR Meetings
1200 -1245
LUNCH BREAK
LUNCH BREAK
1245 -1400
Cont.
MSUS Workshop
Day 2
Cont.
MRI Imaging Course
Day 2
Cont.
GRAPPA Symposium
Cont.
Allied Health Course
APLAR Meetings
1400-1700
AFTERNOON TEA
Industry pre-congress workshop 1
Industry pre-congress workshop 2
Industry pre-congress workshop 3
APLAR Meetings
ROOM
Capacity
PLENARY/CONCURRENT 1 - Exhibition Hall 1
2,000 capacity
1700-1800
Opening Ceremony
ROOM
Capacity
Exhibition Hall 3 - exhibition
1800-1930
Welcome Reception and Official Opening of Exhibition Hall
0800-0930
Plenary session 1
Chairpersons: Catherine Hill and Masayoshi Harigai

Insights into the paradoxical effect of smoking on Behcet's disease
Alireza Khabbazi

TNF inhibitors and JAK inhibitors:which is better for relapsed Takayasu's arteritis
Xinping Tian

Geo-ethnic variations in vasculitis disease
Debashish Danda
0930-1030
Plenary session 2
Chairpersons: Ho So and Ajchara Koolvisoot

What do we learn about the nature of scleroderma disease from the EU-US and Asia-Pacific database?
Andrea Low

Update of guidelines on treatments of interstitial lung disease in connective tissue diseases from ERS/EULAR
Oliver Distler
1030-1055
BREAK AND POSTER VIEWING
1055-1200
Morning symposium 1
For industry program information click here
1200-1315
Concurrent sessions
SpA / PsA session
Chairpersons: Nazrul Islam and Muhammad Ahmed Saeed
Large vessel vasculitis 2023 update
Coordinated by the APLAR Vasculitis SIG
Chairpersons: Debashish Danda and Farzana Shumy
Scleroderma session
Coordinated by the APLAR Scleroderma SIG
Chairpersons: Andrea Low and Jasmin Raja
Insight antiphospholipid syndrome and associated diseases
Chairpersons: Sami Salmon and Kenji Oku
Abstract session: late breaking 1
Chairpersons: Claire Barrett and Galymzhan Togizbayev
Juvenile SpA: pathogenisis, assessment and outcome
Amita Aggarwal

Gut dysbiosis in axial spondyloarthritis
Hong Ki Min

Novel treatment algorithms in axial spondyloarthritis - what is the current status?
Xenofon Baraliakos

Q&A
Opening remarks
Farzana Shumy

Epidemiology and clinical features of GCA
Catherine Hill

Management of GCA
Frank Butthereit

Takayasu arteritis and reproduction
Takako Miyamae

Panel discussion
Catherine Hill, Frank Butthereit, Takako Miyamae and Masayoshi Harigai

Closing remarks
Debashish Danda
Novel therapies in SSc and lessons learnt from clinical trials
Oliver Distler

Bridging the valley of death from bench to bedside in systemic sclerosis
Tohru Takeuchi

Q&A

A challenging therapeutic case of SSc panel discussion
ChingChing Foocharoen, Oliver Distler and Tohru Takeuchi
Update in pathogenesis and relevance antibodies
Takao Koike

Controversy of APS in SLE
Laniyati Hamijoyo

Clinical features and treatments in interferon-driven APS-SLE
Yoshiya Tanaka
Circulating Plasma derived exosomes from Systemic Lupus Erythematosus aggravate lupus nephritis through miR-122-5p/FOXO3-mediated macrophage activation
Juan Ji

Overexpression of miR-20a-5p in mesenchymal stem cell exosomes from systemic lupus erythematosus patients restored therapeutic effect and Treg immune regulation
Juan Ji

Efficacy and Safety of Low-Dose Interleukin 2 for Behçet’s Syndrome:A Randomized Controlled Trial
Tian Liu

Correlation of Pulmonary Function test and Automated CT analysis by CALIPER in CTD-related ILD: A Cross-Sectional Study
Aditi Patankar

Serum alpha-1 antitrypsin in diagnosis and prognosis of antiphospholipid syndrome
Yuebing Wang

Serial imaging changes in skeletal muscle composition and their association with clinical outcomes in idiopathic inflammatory myopathies
Chengappa Kavadichanda
1315-1435
Lunch symposium 1
BREAK AND POSTER VIEWING
Meet the Expert 1
For industry program information click here.
Chairperson: Tasanee Kitumnuaypong (F, Thailand) and Jerusha Naidoo

Unmet needs in SLE
Alberta Hoi

Sponsored by GSK

1435-1550
Concurrent sessions
Axial manifestation of psoriatic arthritis
Chairpersons: Sang-Heon Lee and Praveena Chiowchanwisawakit
Myositis session
Coordinated by the APLAR myositis SIG
Chairpersons: Iris Tang and Takahisa Gono
Paedatric rheumatology workforce: fill the gap session
Coordinated by the APLAR Paediatric SIG
Chairpersons: Caifeng Li and Elizabeth Ang
Genetics session
Coordinated by the APLAR Genetics SIG
Chairpersons: Michael Tee and Chikashi Terao
Abstract session: late breaking 2
Chairpersons: Hung Nguyen and Kanon Jatuworapruk
Clinical features of axial manifestation of psoriatic arthritis
Ved Chaturvedi

The immune landscapes of psoriatic arthritis
Katy Leung

Treatment of axial PsA
Lai-Shan Tam
Myositis related ILD: from bench to bedside
Takuya Kotani

Improving IIM classification criteria: where are we now?
Jessica Day

Myositis histopathology: what clinicians need to know
Xin Lu

Q&A
Opening remarks

Innovations in training
Sirirat Charuvanij

Models of e-learning RAJ
Masaki Shimizu

How to treat series: on-line courses
Kowsar Asna Ashari

COE: blueprint for lesser mortals
Surjit Singh

Q&A
Genetic approach to identify new targeted therapies in SLE
Prapaporn Pisitkun

Personalised medicine in rheumatology: leveraging genetic insights to disease predict
Yi-Ming Chen

Genetic polymorphism in rheumatoid arthritis
Suleman Khan

Q&A
Ultrasound as noninvasive procedure for the diagnosis of Calcium Pyrophosphate Deposition Disease: a new window
Farzana Shumy

Long non-coding RNA ITGB8-AS1 inhibits rheumatoid arthritis synovial inflammation by negatively regulating TGFβ/RAC1 pathway
Yipeng Han

Overexpression of IFNγ Genes Identified by Single-Cell Transcriptomics in Patients with Rheumatoid Arthritis
Hyoun Kim

Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren's Syndrome Revealed by Molecular Classification of Salivary Glands
Huji Xu

Characteristics of dry eye with autoimmune features (DEAF): a cross-sectional study of a single center
Zeng Yuqing
1550-1615
BREAK AND POSTER VIEWING
1615-1730
Concurrent sessions
EULAR session: Early diagnosis and management of arthritis
Chairpersons: Yoshiya Tanaka
Clinical immunology and rheumatology
Coordinated by the AYR SIG
Chairpersons: Priscilla Wong and Himantha Atukorale
Rheumatology potpourri 1
Chairpersons: Steven Sawyers and Nuntana Kasitanon
Women's Health & Reproductive Issues in RMDs
Coordinated by the Reproductive SIG
Chairpersons: Rohini Handa and Saira Khan
Abstract session: late breaking 3
Chairperson: Hung Nguyen and Worawit Louthrenoo
A journey through recent EULAR management recommendations
Anna-Maria Iagnocco

Early RA diagnosis - where are we now?
Daniel Aletaha

Modern imaging tools for early SpA diagnosis
Xenofon Baraliakos

Q&A
Immunodeficiencies presenting to the rheumatology clinic
Justina Tan

Updates in immunoglobulin replacement
Valerie Chiang

A novel approach to anti-cytokine sydnromes - when autoimmunity presents as infections out of the blue
Xin Li

Q&A
Biomarker and immunology aspect in fibromyalgia
Geoffrey Littlejohn

Metabolomic in rheumatic diseases
Ramnath Misra

Sleep disorders in rheumatic diseases
Zhifeng Gu
Introduction into pregnancy and rheumatic disease with focus on SLE and APLS
Samar Al-Emadi

Inflammatory arthritis including RA, SpA (efect of the disease on pregnancy and fetal comes)
Mu Rong

Safety of medication during pregnancy and lactations
Alberta Hoi

Q&A
Evaluating Distinct T Cell Subset Levels and Their Post-Treatment Dynamics as Potential Biomarkers for Immune-Related Adverse Events in Immunotherapy
Yifan Wang

Lymphatic vessels drain monosodium urate and involve in the regression of gouty arthritis
Luying Yuan

Shentong Zhuyu Decoction Alleviates Gouty Arthritis Through Inhibiting MAPK/NLRP3/IL-1β Signaling Pathway
Luying Yuan

Machine learning in clinical predictive models for infection of lupus nephritis
Jiaqian Zhang

Response of low dose IL2 in patients with systemic lupus erythematosus---a real-word study
Ruiling Feng

Real-world Safety and Effectiveness of SB5 (adalimumab biosimilar) for Rheumatic Diseases in South Korea: A Real-world Post-marketing Surveillance Interim Data
Yoon-Kyoung Sung

Development of a list of autoimmune rheumatic diseases and their manifestations for population screening: a consensus development study
Ling Xiang
1745-1845
Evening symposium 2
For industry program information click here
ROOM
Capacity
Exhibition Hall 1
2,000 capacity
Convention Hall 1
1,700 capacity
Leelawadee Hall 1
400 theatre capacity
Leelawadee Hall 2
400 theatre capacity
B1
100 theatre capacity
Exhibition Hall 3
0800-0900
0900-1030
1030-1055
BREAK AND POSTER VIEWING
1055-1200

Morning symposium 1
Sponsored by AbbVie

Morning symposium 2

Morning symposium 3

Morning symposium 4
1200-1315
Concurrent session
SIG Rheumatoid arthritis
Concurrent session
SIG Vasculitis
Concurrent session
COVID-19 infection and rheumatic diseases
Concurrent session
Personalized treatment in idiopathic inflammatory myopathy (IIM)
Concurrent session
SIG Sjogren
1315-1435

Lunch symposium 1
Sponsored by Pfizer

Lunch symposium 2
1320-1350
Meet the experts 1
Sponsored by GSK
1400-1430
Meet the experts 2
Sponsored by Boehringer Ingelheim
1435-1550
Concurrent session
1. Update treatment in osteoporosis
Sequential and combination of osteoporosis therapy
Denosumab discontinuation

2.Osteoporosis treatment and cardiovascular effects
Relationship of bone and cardiovascular system
Cardiovascular effects of osteoporosis therapies
Concurrent session
SIG Myositis
Update on idiopathic inflammatory myopathy diagnosis

From pathology to diagnosis
Myositis specific antibodies in IIM and clinical relevance
Concurrent session
SIG Pediatric
Children with rheumatic diseases during COVID-19 era

Immunogenicity and effectiveness of COVID-19 vaccination
Outcomes of autoimmune diseases after COVID-19 infection/vaccination
Concurrent session
IgG4 related disease
Updated mechanisms Perspective treatment Myositis specific antibodies in IIM and clinical relevance
0800-0900
Concurrent sessions
Advanced therapy in rheumatic diseases
Chairpersons: Lai-Shan Tam and Andrea Low
Abstract session 1: Antiphospholipid syndrome
Chairperson: Pintip Ngamajanyaporn
Abstract session 2: Autoinflammatory disease / paediatric
Chairperson: Soamarat Vilaiyuk
Abstract session 3: Miscellaneous
Chairperson: Chit Soe
Treatment of non-radiographic axial spondyloarthritis: which kinds of medicine should be the most appropriate treatment for non-radiographic axial spondyloarthritis and when to start?
Mitsumasa Kishimoto

Q&A

Advances in targeted therapy in rheumatic diseases
Anna-Maria Hoffmann Vold

Q&A
The Subtype and Prognosis of Acute Myocardial Infarction in Antiphospholipid Syndrome patients
Can Huang

Plasma lipidomics analysis reveals the distinguishing pathogenesis between arterial and venous thrombosis in patients with antiphospholipid syndrome
Hui Jiang

Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Yin Long

Cluster analysis of antiphospholipid antibodies associated adverse pregnancy outcome patients: based on a 13-year longitudinal cohort study
Yin Long

Oxidized Low-Density Lipoprotein and antibodies against Oxidized Low-Density Lipoprotein in Patients With Antiphospholipid Syndrome
Yongjing Luo
Presenting Features of Rheumatic diseases in Children- Single Center Experience from western India
Deepti Agarwal

The safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of retrospective cohort two-centered study
Mikhail Kostik

The diagnostic cut-off for discrimination of nonbacterial osteomyelitis from other bone destructive diseases
Mikhail Kostik

The proximity-enabled covalent binding of IL-2 to IL-2Rα selectively and persistently augments its effects on Tregs and suppresses autoimmune pathologies
Yeting Sun

Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with rheumatic diseases: a retrospective cohort study
Weijie Wang

Chronic Recurrent Multifocal Osteomyelitis (CRMO) in a tertiary center in Iran; a case series and review of the literature
Kosar Asna Ashari
Machine Learning Models Identify Gut Microbiota that Predict Chronicity in Reactive Arthritis
Sakir Ahmed

Risk Factors for Plantar Fasciitis: A Case Control Study Among Patients Attending Rheumatology Clinic
Anushka Ediriweera

The Largest Asian GWAS and the HLA Study for Systemic Sclerosis Identified a Novel High-Risk Locus and the HLA-DRB1 Association
Yuki Ishikawa

Serum uric acid and lung function in NHANES dated from 2007 to 2012: A cross-sectional research
Tianlun Kang

Deep Learning Approaches to Rheumatoid Arthritis Severity Prognosis
Isaac Zachary To

Clinical prediction score of sustained remission to methotrexate therapy in patients with early rheumatoid arthritis
Sujin Lertwises
0900-1030
Plenary session 3
Chairpersons: Rohini Handa and Yi-Hsing Chen

Rational DMARDs use in Asian context
Tsutomu Takeuchi

How to taper and/or discontinue DMARDs (csDMARDs, biologics and JAKi) in RA patients with sustained remission
Daniel Aletaha

Non-selective vs selective JAK inhibitors for RA: effectiveness and safety
Peter Nash
1030-1100
BREAK AND POSTER VIEWING
1100-1200
Concurrent sessions
Deep insight in SLE
Chairpersons: Atsushi Kawakami and Prapaporn Pisitkun
Personalized treatment in idiopathic inflammatory myopathy (IIM)
Chairpersons: Latika Gupta and Jasmin Raja
Rheumatology Potpourri 2
Chairpersons: Yi-Hsing Chen and Nuntana Kasitanon
Abstract session 4: Osteoarthritis / Osteoporosis / Crystal arthropathies

Chairperson: Kanon Jatuworapruk
Optimising glucocorticoid therapy in SLE
Sandra Navarra

Q&A

Insight biologic therapy in SLE
Yoshiya Tanaka

Q&A

Measuring disease activity in lupus clinical trials: finding the right metrics for success
Eric Morand

Q&A
IIM associated ILD
Hideaki Tsuji

What's new in anti-MDA5 dermatomyositis?
Ho So
Renal and neurological problems in Sjogren's syndrome
Sandhya Pulukool

Imaging in large vessel vasculitis
Naoto Tamura
Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)
Benny Antony

Reconstruction of the intra-articular environment of osteoarthritis in a 3d co-culture system
Gunil Im

Causal Relationships Between Body Mass Index and Osteoarthritis Disease: A Bidirectional Mendelian Randomization Study
Feng Jiang

HU values from vertebral CT for the diagnosis of osteoporosis: a systematic review and meta-analysis
Feng Jiang

A double-blinded randomized controlled study comparing non-loading versus loading low-dose oral colchicine in acute crystal-associated arthritis
Ployrung Laosuksri

Novel insights into the osteoclast regulatory system
Masayuki Tsukasaki
1200-1315
Concurrent sessions
Osteoarthritis session
Coordinated with the APLAR Osteoarthritis SIG
Chairpersons: Keith Lim and Sumapa Chaiamnuay
Recent advances in psoriatic arthritis
Coordinated by the APLAR SpA SIG
Chairpersons: Nizar Abdulateef Jassim and Kichul Shin
Social commitment and patient outreach session
Coordinated by the Social commitment and patient outreach SIG
Chairpersons: Syed Atiqul Haq and Nighat Ahmad
Abstract session 5: Rheumatoid Arthritis
Chairperson: Wunrachada Katchamart
Joint effusions and knee OA
Keith Lim

Inflammatory phenotype of osteoarthritis and potential therapies
Changhai Ding

Predictors of clinical response8 in osteoarthritis
Benny Antony

Q&A
State of the art therapeutics for PsA
Lai-Shan Tam

Precision medicine in predicting treatment response in psoriatic arthritis
Ippei Miyagawa

Role of MRI in PsA
Ashish Mathew

Q&A
Introduction
Syed Atiqul Haq and Nighat Ahmad

Educating patients: show should a rheumatology proceed
A T M Tanveer Hasan

The HomeRheum Status: Current state of rheumatology workforce in Asia-Pacific
Jonathan Paul Consignado

Q&A

Closing remarks
Syed Atiqul Haq and Nighat Ahmad
Significant association of plasma levels of galectin-9 and soluble TIM-3 with non-alcoholic fatty liver disease in patients with rheumatoid arthritis
Po-Ku Chen

Whole-exome sequencing revealed variants of NLR-related and SLX-related genes as predictors of remission with tofacitinib therapy in rheumatoid arthritis patients
Der-yuan Chen

Fatty acid synthase is a critical repressor of ferroptosis in rheumatoid arthritis
Qi Cheng

25-hydroxycholesterol in the pathogenesis of rheumatoid arthritis
Hong Huang

Immunophenotyping of rheumatoid arthritis (RA) stratifies five subgroups and reveals pathogenic CD4 T cell subset
Satoshi Kubo

Synovial tissue heterogeneity and predominant inflammatory signal in Japanese patients with rheumatoid arthritis
Sotaro Nakajima

Novel associations between fibroblast growth factor 23 levels and RF and IFN-γ in rheumatoid arthritis
Ryu Watanabe
1315-1435
Lunch symposium 3
BREAK AND POSTER VIEWING
For industry program information click here
1435-1550
Concurrent sessions
Best management of SLE
Coordinated by the SLE SIG
Chairpersons: CC Mok and Yoshiya Tanaka
Rheumatoid arthritis session
Coordinated by the RA SIG
Chairpersons: Kunihiro Yamaoka and Zhanguo Li
Emerging treatment strategies for osteoporosis
Coordinated by the Osteoporosis SIG

Chairpersons: Lau Tang Ching and Sumapa Chaiamnuay
Abstract session: Late breaking 4
Chairperson: Emmanuel C. Perez
Impact of ethnic and social inequity on outcome of SLE
Sarfaraz Hasni

Assessment of disease activity of SLE
Kathryn Connelly

COVID-19 in SLE
Syahrul Sazliyana

Q&A
Recommendation update
Kunihiro Yamaoka

Improvement of early diagnosis and management of rheumatoid arthritis using digital health system
Chun Li

Q&A
What is hot and what is not in bone?
Kenneth Saag

Case discussion on sequential vs combination therapy
Julie Yu

Debate - treat or target for osteoporosis, myth or reality?
Lau Tang Ching and Sumapa Chaiamnuay

Q&A
Consensus Recommendations for Referral, Diagnosis, Monitoring, and Management of Axial Spondyloarthritis in the Gulf Countries
Khalid Alnaqbi

Efficacy and Safety of Tofacitinib in the Treatment of NSAIDs-Refractory Axial Spondyloarthritis: A Clinical Trial
Md Nahiduzzamane Shazzad

Effectiveness and safety of upadacitinib in patients with active ankylosing spondylitis: results from the Russian registry racurs
Tatiana Dubinina

Efficacy of oral steriods for peripheral arthritis in spondylarthritis: a double blind, parallel group, randomised control trial
Sankar Jayaprakash

Germanium Telluride-Polyvinylpyrrolidone Nanosheets ameliorate inflammatory response in inflammatory disease model
Yong-Beom Park

Transforming Calcinosis in Juvenile dermatomyositis: Tofacitinib’s impact- A case series
Anand Sasidharan
1550-1620
BREAK AND POSTER VIEWING
1620-1735
Concurrent sessions
Current evidence of osteoarthritis management
Chairpersons: Nazrul Islam and Keith Lim
Digital health and clinical decision support system in rheumatology Best management of SLE
Coordinated by the Digital Health and Telemedicine SIG
Chairpersons: Yew Kuang Cheng and Anindita Santosa
Crystal induced arthritis session
Coordinated by the Crystal induced arthritis SIG
Chairpersons: Helen Keen and Jose Paulo Lorenzo
Abstract session 7: Systemic lupus erythematosus
Chairperson: Rattapol Pakchotanon
Update pathogenesis of osteoarthritis
Inoshi Atukorala

Update treatment in osteoarthritis
Syed Atiqul Haq

What's new in hand osteoarthritis?
Benny Antony
Why should we use artificial intelligence in rheumatic disease?
Sakir Ahmed

Artificial intelligence implication in rheumatic diseases
Lisa Traboco

Q&A
The intersection of gout and chronic kidney disease
Evelyn Salido

Gaps in the current knowledge of evaluation and treatment of gout
Binit Vaidya

CPPD the ignored disease
Sami Salmon

APLAR gout registry updates and preliminary results
Kanon Jatuworapruk

Q&A
The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus
Yufang Ding

Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction
Yufang Ding

Taiwan Consensus Recommendations on the Management of Systemic Lupus Erythematosus
Wen-Nan Huang

Can KidneyHistopathology predict disease flares following drug withdrawal in Proliferative LupusNephritis?Subgroup analysis of a Randomised drug withdrawal trial in SLE
Chengappa Kavadichanda

Antiphospholipid Antibodies As Potential Predictors Of Disease Severity And Poor Prognosis In Systemic Lupus Erythematosus Associated Thrombocytopenia
Jun Li

Climate Change and Haze in Malaysia: Impact on Systemic Lupus Erythematosus (SLE) disease activity
Shaharir Syahrul Sazliyana

Efficacy and Safety of ABBV-599 High Dose and Upadacitinib Monotherapy for Systemic Lupus Erythematosus: A Phase 2 Trial
Yoshiya Tanaka
1735-1850
Concurrent sessions
Gout in women
Chairpersons: Jose Paulo Lorenzo and Worawit Louthrenoo
Pain in rheumatic musculoskeletal disorders: A COPCORD perspective
Coordinated by the Epidemiology COPCORD SIG
Chairpersons: Arvind Chopra and Samar Al-Emadi
Chronic pain session
Coordinated by the Chronic pain SIG
Abstract session 8: Spondylarthropathies
Chairperson: Samina Ghaznavi
Urate biology
Helen Keen

Clinical presentations and management
Monika De Silva

Patient preferences in gout management
Jisoo Lee
What a pain it is!
Arvind Chopra

Pain beyond inflammation in rheumatic disorders
Shin-Seok Lee

Lessons on capturing pain from COPCORD studies
Leonila Dans

Epidemiology of fibromyalgia in rheumatic diseases
Soosan Soroosh

Sex differences in perception of pain in the COPCORD domain
Binit Vaidya

Future COPCORD research agenda for pain in rheumatic diseases
Ashish Mathew

Q&A
Chronic Musculoskeletal pain in Diabetes malitus- a spectrum with a difference
Sabrina Yesmin

Fibromyalgia, then and now
Sundeep Upadhyaya

Community based study of prevalence and social factors for chronic pain and fibromyalgia in women from western India
Sandeep Kansurkar

Q&A
Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients With Active Psoriatic Arthritis in Japan
Momoko Inoue

Value of low-dose computed tomography for examination of sacroiliac joints in axial spondyloarthritis
In-woon Baek

Are we treating-to-target in spondyloarthritis(SpA)? A one-year analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
Isaac T Cheng

Utility of a multi-biomarkers panel on predicting disease activity in patients with psoriatic arthritis – a derivation and validation study
Yingzhao Jin

Domains Impacting Minimal Disease Activity Non-achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNFi Receiving Guselkumab (COSMOS)
Kevin Pile

Performance of various definitions for active MRI lesions in sacroiliac joint and spine in discriminating patients with axial psoriatic arthritis
Xianfeng Yan

Bimekizumab in the Chinese Subpopulation of Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results from BE MOBILE 2
Huji Xu
1930-2130
Joint Presidential & Gala Dinner
Not included in registration. Tickets available at additional cost. View more information and registration information here
0800-0900
Concurrent sessions
Gout session
Chairpersons: Helen Keen and Ronald Yip
Relapse of adult-onset Still disease
Chairpersons: Wafa Wadanat and Samar Al-Emadi
Abstract session 9: Systemic vasculitis / Sjogren syndrome
Chairpersons: Alakendu Ghosh and Pichaya O-Charoen
Abstract session 10: Scleroderma / Myositis
Chairpersons: Uma Kumar and Chayawee Muangchan
Cardiovascular morbidity in gout
Jose Paulo Lorenzo

Emerging strategies for treating difficult gout
Worawit Louthrenoo
Genetics and risk factors
Alireza Khabbazi

How to treat and efficacy of tight control
Dae Hyun Yoo
Fecal Calprotectin and the Complications of Immunoglobulin (Ig)A-mediated vasculitis: A Cross-sectional Study
Elaheh Baharvand Ahmadi

Deltex1, a T cell anergy regulator, may be a biomarker of disease activity in Sjögren’s syndrome
Ming-Han Chen

Risk factors for serious infections and infection-related mortality in patients with microscopic polyangiitis: a multicenter retrospective observational cohort study
Atsushi Manabe

Lysosome-associated membrane protein 3 expression is involved in enhanced type I interferon response in Sjögren’s syndrome
Hiroyuk Nakamura

Real-world Effectiveness of Interleukin-6 Receptor Inhibitors in patients with Steroid Refractory Polymyalgia Rheumatica
Hubert van Hoogstraten

Sustained Remission From Weeks 16 and 24 to Week 52 in Patients With Polymyalgia Rheumatica Receiving Sarilumab: SAPHYR Post-hoc Analysis
Hubert van Hoogstraten
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: the ILD-RISC Score
Oliver Distler

Consistency between enzyme-linked immunosorbent assay and line blot assay in myositis-specific autoantibody in patients with Idiopathic inflammatory myopathies
Takahisa Gono

Interstitial Lung Diseases Among Idiopathic Inflammatory Myopathies Patients In Hong Kong
Iris Yan Ki Tang

Comparison of clinical and laboratory differences between Thai SSc patients with myocardial edema and fibrosis determined by cMRI: preliminary report
Suparaporn Wangkaew

Clinical heterogeneity in patients with anti-synthetase antibodies
Shintaro Yamamoto
0900-1030
Plenary session 4
Chairpersons: Laniyati Hamijoyo and Sandra Navarra

Future direction of optimal treatment in SLE
Eric Morand

Charting the Enigmatic Course of Lupus: Discovering New Pathogenesis Pathways and Aiming at Innovative Therapeutic Targets
Nan Shen

New concepts of lupus nephritis treatment
CC Mok
1030-1050
BREAK AND POSTER VIEWING
1050-1205
Concurrent sessions
Hot topics in rheumatoid arthritis
Chairpersons: Manathip Osiri and Cho Mar Lwin
Imaging SIG session
Chairpersons: Kok Ooi and Phonpen Akarawatcharangura Goo
Highlights in Paediatric Rheumatology
Chairpersons: Sumaira Farman and Thaschawee Arkachaisri
Abstract session 11: Systemic lupus erythematosus - basic

Chairpersons: Sumaira Farman and Prapaporn Pisitkun
Advances in biological targets in RA
Kazuhiko Yamamoto

Should csDMARDs be maintained lifelong after sustained remission?
Mu Rong
Ultrasonography in large vessel vasculitis (US LVV) - an update
Helen Keen

Rheumatology ultrasonography (RUS) training in APLAR – a proposed framework
Gavin Lee

Ultrasonography in Systemic Lupus Erythematosus
Farzana Shumy

Q&A
Cytokine storms: similarities and dissimilarities between MAS and MIS-C
Soamarat Vilaiyuk

COVID-19 vaccination in pediatric rheumatic diseases: where are we going forward?
Thaschawee Arkachaisri

Autoinflammatory diseases in Asian Pacific: are we different?
Sulaiman Al-Mayouf
Identification of hub genes that predict response to cyclophosphamide based treatment in proliferative lupus nephritis
Sree Nethra Bulusu

Unravelling the Complexity of Systemic Lupus Erythematosus (SLE): High-dimensional Interrogation of the adult and paediatric patient immunomes
Katherine Nay Yaung

Increased proportion of ICOS-expressing follicular helper1 CD4+T cells is associated with high disease activity in systemic lupus erythematosus patients
Tipanan Khunsri

Expression of interferon- stimulated genes (ISGs) in patients with systemic lupus erythematosus (SLE) for therapy personaliztion and prognosis
Zinaida Mutovina

Different type I interferon stimulated gene signatures respond differently to the glucocorticoid treatment
Koichiro Ohmura

Clinical and transcriptomic characteristics in a humanized mouse model for systemic lupus erythematosus personalized medicine
Xiaolin Sun

Analysis of multicolor flow cytometry on the changes of peripheral blood lymphocyte subsets in elderly patients with systemic lupus erythematosus
Chi Sun
1205-1305
BREAK AND POSTER VIEWING
1305-1420
Concurrent sessions
Updating Imaging in rheumatology
Chairpersons: Katy Leung and
ACR / APLAR session
Chairperson: Yoshiya Tanaka
Reproductive aspects in rheumatic disease
Chairpersons: Chang-Youh Tasi
Abstract session 12: Rheumatoid arthritis
Chairperson: Parawee Chevaisrakul
Imaging modalities for CNS vasculitis evaluation
Naoto Tamura

Imaging update in spondyloarthritis
Ashish Jacob Mathew

Imaging update in osteoarthritis
Hyun Ah Kim
Therapeutic challenges in gout
Kenneth Saag

Are the newer treatments in lupus nephritis improving outcomes
Sarfaraz Hasni

Q&A
Reproductive health in inflammatory arthritis
Samar Al-Emadi

Reproductive health and biologics
Latika Gupta

Pregnancy outcomes in SLE
Sandra Navarra
Exploring the Impact of Dietary Patterns, Knowledge, and Lifestyle on Joint Health in Elderly Rheumatoid Arthritis Patients in Chongqing, China
Xi Zhang

Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): the Multicenter/Randomized/Double-blinded/Placebo-controlled/Phase 2a IRIS-RA Study
YoungJa Lee

Clinical prediction score of sustained remission to methotrexate therapy in patients with early rheumatoid arthritis
Sujin Lertwises

Efficacy of Methotrexate in Combination with Antioxidant Vitamins (A, C and E) versus Methotrexate alone in Treatment of Rheumatoid Arthritis
Md Kamrul Hasan Lohani

The Cardiovascular Risk of JAK inhibitors in Treating Rheumatic Disease
Alexander Kwan

Clinical and patient-reported outcomes for tofacitinib in rituximab-experienced patients with rheumatoid arthritis: results from the CorEvitas Rheumatoid Arthritis Registry
Manathip Osiri
1420-1440
BREAK AND POSTER VIEWING
1440-1555
Concurrent sessions
COVID-19 and beyond
Chairpersons: Kichul Shin
Recent understanding and perspective of Sjogren's syndrome
Coordinated by the APLAR Sjogren SIG
Chairpersons: Sapan Padya
What's new in osteoporosis?
Chairpersons: Sumapa Chaiamnuay and Lau Tang Ching
Abstract session 13: Spondyloarthropathies
Chairperson: Ajanee Mahakkanukrauh
Autoimmunity after COVID infection
Prapaporn Pisitkun

Comparative outcome of patients with rheumatic disease affected by COVID-19 infection
Kuo-Tung Tang
GWAS in Sjogren
Maureen Rischmueller

Recent understanding and perspective of Sjogren's syndrome
Atsushi Kawakami

Q&A
Epidemiology of bone health in patients with rheumatic diseases
Arvind Chopra

New evidence of bone safety of glucocorticoids in the treatment of inflammatory rheumatic disease
Kenneth Saag

Long-term management strategies for osteoporosis: continuous or intermittent?
Kosuke Ebina
Placebo-Controlled Efficacy and Safety of Upadacitinib Through One Year in Patients With Non-Radiographic Axial Spondyloarthritis
Lai-Shan Tam

Ankylosing spondylitis is associated with increased prevalence of valvular heart diseases: a cross-sectional population-based study
Mohammad Adawi

Efficacy and Safety of Tofacitinib and its comparison with Secukinumab in Axial SpA patients
Muhammad Arshad

Treat-to-target in spondyloarthritis (SpA): Are there sex-related differential responses?
Carson Yip

Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar
Jin-xian Huang

Discriminatory cytokine profile in active ankylosing spondylitis
Jin-xian Huang

Are Functional Ability, Quality of Life, and Clinical Measurements related to Disease Activity in Patients with Early-treated Axial Spondyloarthritis
Tinh Khampaen
1555-1625
Closing Ceremony
Translate »
  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

The countdown is on

Have you registered yet? Don't miss your chance on attending live sessions featuring the latest, best-in-class research and provide an opportunity to connect and stay apprised of the latest developments and innovations in the field.

Welcome to APLAR 2023

Hear from our APLAR cohort on the upcoming congress updates along with APLAR initiatives.